Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system,
offering each year of continuous glucose monitoring for just
$200*
PARSIPPANY, N.J., March 12,
2024 /PRNewswire/ -- Ascensia Diabetes Care, a global
diabetes care company and a subsidiary of PHC Holdings Corporation
(TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a
medical technology company focused on the development and
manufacturing of long-term, implantable continuous glucose
monitoring (CGM) systems for people with diabetes,
have announced a significant extension of the Eversense
Payment Assistance and Simple Savings (PASS) Program. Designed to
help people in the U.S. access the Eversense E3 CGM System more
affordably, the program offers major savings for eligible
individuals looking to experience the unique benefits of the only
long-term CGM system available.
Eligible individuals will pay only $99 out of pocket for an unlimited number of
6-month Eversense E3 systems, under this program. This is
equivalent to an average monthly cost of $16.50 and a total out-of-pocket cost of less
than $200 for each entire year of
continuous glucose monitoring with Eversense E3, excluding the
costs of insertion and removal.
The Eversense PASS Program was first introduced in April 2022 to cover one initial Eversense
system, which includes a sensor and transmitter. In May 2023 the $99 offer was extended to cover a whole year of
continuous glucose monitoring, through the first two
sensor/transmitter combinations, and expanded its eligibility to
include more commercially insured people with diabetes. Following
the success of this program, those who are eligible will now be
able to access these savings for all further Eversense E3 systems
as long as this program remains in effect.
"Traditional, short-term CGMs don't work for everyone, and we
are proud to bring a truly unique CGM option in Eversense E3 to
people with diabetes," said Rudy
Thoms, VP, CGM Commercial U.S. at Ascensia Diabetes Care.
"We are significantly extending the Eversense PASS program to
provide major savings for people in the U.S., beyond when they
first try the 6-month CGM to their subsequent Eversense E3 CGM
systems. We believe that long-term CGMs are the future, and so we
are pleased to further improve access to and affordability of
Eversense, allowing more people to experience the future
today."
Designed by Senseonics and brought to people with diabetes by
Ascensia, the Eversense E3 CGM System offers a fully implantable
option that is highly differentiated from traditional CGMs:
- The longest lasting CGM available, with up to 6-month
sensor wear duration and two sensor insertion and removal
procedures per year
- Exceptional accuracy for the entire duration of sensor wear**,
including high accuracy during high/low glucose events, which is
crucial for effective treatment
- The only CGM with a removable transmitter which can
be taken on and off without wasting a sensor or adding a warm up
period†
- The only CGM with predictive on-body alerts to help avoid
missing a critical event, especially at night while sleeping or
when away from your phone
Eligibility & Exclusions Overview:
- Eligibility: To be eligible, a person must have a commercial
insurance plan, with or without coverage for the Eversense E3
CGM. They must also meet medical coverage criteria for CGM as
indicated by their insurance provider.
- Exclusions: Government insurance as primary or secondary
coverage (i.e., Medicare, Medicare Advantage, Medicaid,
and Tri-Care) or commercial insurance plans that
require purchase directly from HCPs (Health Care
Professionals) via global payment.
Potential Eversense E3 users can go to
www.ascensiadiabetes.com/eversense to learn more about the product
and go to
https://www.ascensiadiabetes.com/eversense/coverage/patient-assistance-program-information/
to learn more about the program and find out if they are
eligible. Physicians, nurse practitioners and physician
assistants who are interested in learning more about the Eversense
E3 CGM System can sign up at
https://www.ascensiadiabetes.com/eversense/become-a-provider/.
Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more
about the first and only long-term implantable CGM system. The PASS
program is subject to modification, change or termination at any
time.
* This cost is for the Eversense E3 CGM system
only and excludes the cost of insertion and removal
** A mean absolute relative difference (MARD) of 8.5%
demonstrated in the PROMISE Study (Garg S. et al. Evaluation of
Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term
Implantable Eversense Continuous Glucose Monitoring System: The
PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2):
1-9.DOI: 10.1089/dia.2021.0182)
† There is no glucose data generated when
the transmitter is removed
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is
a global company focused entirely on helping people with diabetes.
Its mission is to empower those living with diabetes through
innovative solutions that simplify and improve their lives. It is
home to the world-renowned CONTOUR® portfolio of blood
glucose monitoring systems and the exclusive global distribution
partner for the Eversense® Continuous Glucose Monitoring
Systems from Senseonics. These products combine advanced technology
with user-friendly functionality to help people with diabetes
manage their condition and make a positive difference to their
lives. As a trusted partner in the diabetes community, it
collaborates closely with healthcare professionals and other
partners to ensure its products meet the highest standards of
accuracy, precision and reliability, and that it conducts its
business compliantly and with integrity. Ascensia is a member of
PHC Group and was established in 2016 through the acquisition of
Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products
are sold in more than 100 countries. Ascensia has over 1,300
employees and operations in 31 countries. For further information,
please visit the Ascensia Diabetes Care website at:
http://www.ascensia.com
About PHC Holdings Corporation
PHC Holdings
Corporation (TSE 6523) is a global healthcare company with a
mission of contributing to the health of society through healthcare
solutions that have a positive impact and improve the lives of
people. Its subsidiaries (referred to collectively as PHC Group)
include PHC Corporation, Ascensia Diabetes Care Holdings AG,
Epredia Holdings Ltd., LSI Medience Corporation, Mediford
Corporation, and Wemex. Together, these companies develop,
manufacture, sell and service solutions across diabetes management,
healthcare solutions, life sciences and diagnostics. PHC Group's
consolidated net sales in FY2022 were JPY
356.4 billion with global distribution of products and
services in more than 125 countries. www.phchd.com
About Senseonics
Senseonics Holdings, Inc.
("Senseonics") is a medical technology company focused on the
development and manufacturing of glucose monitoring products
designed to transform lives in the global diabetes community with
differentiated, long-term implantable glucose management
technology. Senseonics' CGM system Eversense® E3 includes a small
sensor inserted completely under the skin that communicates with a
smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
About Eversense
The Eversense® E3 Continuous Glucose
Monitoring (CGM) System is indicated for continually measuring
glucose levels for up to 180 days in persons with diabetes age 18
and older. The system is indicated for use to replace fingerstick
blood glucose (BG) measurements for diabetes treatment decisions.
Fingerstick BG measurements are still required for calibration
primarily one time a day after day 21, and when symptoms do not
match CGM information or when taking medications of the
tetracycline class. The sensor insertion and removal procedures are
performed by a health care provider. The Eversense E3 CGM System is
a prescription device; patients should talk to their health care
provider to learn more.
For important safety information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
Forward Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
Senseonics, including statements regarding announced changes taking
effect as planned, statements regarding growing the awareness,
adoption, growth and potential of Eversense, and other statements
containing the words "believe," "expect," "intend," "may,"
"projects," "will," "planned," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
in insurer, regulatory and administrative processes and decisions,
uncertainties inherent in the ongoing commercialization of the
Eversense product, uncertainties inherent in Ascensia's performance
and other commercial initiatives, uncertainties relating to the
current economic environment and such other factors as are set
forth in the risk factors detailed in Senseonics' Annual Report on
Form 10-K for the year ended December 31,
2023 and Senseonics' other filings with the SEC under the
heading "Risk Factors." In addition, the forward-looking statements
included in this press release represent Senseonics' views as of
the date hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics' views to change. However, while
Senseonics may elect to update these forward-looking statements at
some point in the future, Senseonics specifically disclaims any
obligation to do so except as required by law. These
forward-looking statements should not be relied upon as
representing Senseonics' views as of any date subsequent to the
date hereof.
Logo:
https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/savings-offer-for-the-eversense-e3-cgm-extended-to-cover-unlimited-number-of-systems-302086491.html
SOURCE Ascensia Diabetes Care